Establishment of a circRNA-regulated E3 ubiquitin ligase signature and nomogram to predict immunotherapeutic efficacy and prognosis in hepatocellular carcinoma

被引:0
作者
Wu, Gefeng [1 ,2 ]
Zhang, Jiahao [1 ,2 ]
Peng, Rui [1 ]
Cao, Jun [1 ]
Tu, Daoyuan [1 ]
Zhou, Jie [1 ]
Su, Bingbing [1 ]
Jin, Shengjie [1 ]
Jiang, Guoqing [1 ]
Zhang, Chi [1 ]
Bai, Dousheng [1 ]
机构
[1] Yangzhou Univ, Clin Med Coll, Dept Hepatobiliary Surg, 98 West Nantong Rd, Yangzhou 225000, Jiangsu, Peoples R China
[2] Dalian Med Univ, Dalian 116000, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; CircRNA; E3 ubiquitin ligase signature; Nomogram; Immune and prognosis; PROTEIN; CELLS; PROLIFERATION; REVEAL; MODELS; ROLES;
D O I
10.1186/s40001-024-01893-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Hepatocellular carcinoma (HCC) is a common type of malignant tumor where the prognosis is dismal. Circular RNA (CircRNA) is a novel RNA that regulates downstream gene transcription and translation to influence the progression of HCC. However, the regulatory relationship that exists between E3 ligases, which is a class of post-translational modifying proteins, and circRNA remains unclear.Methods Based on the E3 ubiquitin ligase in the competitive endogenous RNA (ceRNA) network, a circRNA-regulated E3 ubiquitin ligase signature (CRE3UL) was developed. A CRE3UL signature was created using the least absolute shrinkage and selection operator (Lasso) and Cox regression analysis and merged it with clinicopathologic characteristics to generate a nomogram for prognosis prediction. The pRRophetic algorithm was utilized and immunological checkpoints were analyzed to compare the responses of patients in the high-risk group (HRG) and low-risk group (LRG) to targeted therapy and immunotherapy. Finally, experimental research will further elucidate the relationship between E3 ubiquitin ligase signature and HCC.Results HRG patients were found to have a worse prognosis than LRG patients. Furthermore, significant variations in prognosis were observed among different subgroups based on various clinical characteristics. The CRE3UL signature was identified as being an independent prognostic indicator. The nomogram that combined clinical characteristics and the CRE3UL signature was found to accurately predict the prognosis of HCC patients and demonstrated greater clinical utility than the current TNM staging approach. According to anticancer medication sensitivity predictions, the tumors of HRG patients were more responsive to gefitinib and nilotinib. From immune-checkpoint markers analysis, immunotherapy was identified as being more probable to assist those in the HRG.Conclusions We found a significant correlation between the CRE3UL signature and the tumor microenvironment, enabling precise prognosis prediction for HCC patients. Additionally, a nomogram was developed that performs well in predicting the overall survival (OS) of HCC patients. This provides valuable guidance for clinicians in devising specific personalized treatment strategies.
引用
收藏
页数:21
相关论文
共 45 条
[21]   The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma [J].
Yin, Jie ;
Zhu, Ji-Min ;
Shen, Xi-Zhong .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (02) :249-257
[22]   Endothelial senescence-associated secretory phenotype (SASP) is regulated by Makorin-1 ubiquitin E3 ligase [J].
Kotla, Sivareddy ;
Nhat-Tu Le ;
Hang Thi Vu ;
Ko, Kyung Ae ;
Gi, Young Jin ;
Thomas, Tamlyn N. ;
Giancursio, Carolyn ;
Lusis, Aldos J. ;
Cooke, John P. ;
Fujiwara, Keigi ;
Abe, Jun-ichi .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 100
[23]   Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation [J].
Min Liu ;
Ke Jiang ;
Guibin Lin ;
Peng Liu ;
Yumei Yan ;
Tian Ye ;
Gang Yao ;
Martin P. Barr ;
Dapeng Liang ;
Yang Wang ;
Peng Gong ;
Songshu Meng ;
Haozhe Piao .
Journal of Experimental & Clinical Cancer Research, 37
[24]   Integrated GMPS and RAMP3 as a signature to predict prognosis and immune heterogeneity in hepatocellular carcinoma [J].
Chen, Zhuoyan ;
Zeng, Yuan ;
Ma, Peipei ;
Xu, Qian ;
Zeng, Liuwei ;
Song, Xian ;
Yu, Fujun .
GENE, 2025, 933
[25]   E3 ubiquitin ligase Bre1 couples sister chromatid cohesion establishment to DNA replication in Saccharomyces cerevisiae [J].
Zhang, Wei ;
Yeung, Clarence Hue Lok ;
Wu, Liwen ;
Yuen, Karen Wing Yee .
ELIFE, 2017, 6
[26]   The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma [J].
Li, Yu-Hui ;
Zhong, Ming ;
Zang, Hong-Liang ;
Tian, Xiao-Feng .
EXPERIMENTAL CELL RESEARCH, 2018, 368 (01) :37-41
[27]   Proteolytic Degradation of the Yap1 Transcription Factor Is Regulated by Subcellular Localization and the E3 Ubiquitin Ligase Not4 [J].
Gulshan, Kailash ;
Thommandru, Bernice ;
Moye-Rowley, W. Scott .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (32) :26796-26805
[28]   E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing [J].
Chen, De ;
Wang, Yanjie ;
Lu, Ruixun ;
Jiang, Xiaofeng ;
Chen, Xinhui ;
Meng, Nan ;
Chen, Min ;
Xie, Shan ;
Yan, Guang-Rong .
THERANOSTICS, 2020, 10 (19) :8558-8572
[29]   Integrative analysis identified two subtypes and a taurine-related signature to predict the prognosis and efficacy of immunotherapy in hepatocellular carcinoma [J].
Lu, Qingsong ;
Lou, Yu ;
Zhang, Xiaozhen ;
Yang, Hanshen ;
Chen, Yan ;
Zhang, Hanjia ;
Liang, Tingbo ;
Bai, Xueli .
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2023, 21 :5561-5582
[30]   Hint1 Up-Regulates IκBα by Targeting the β-TrCP Subunit of SCF E3 Ligase in Human Hepatocellular Carcinoma Cells [J].
Shi, Zhitian ;
Wu, Xuesong ;
Ke, Yang ;
Wang, Lin .
DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (03) :785-794